Designing microbiome therapies at scale starts with manufacturing Drug Discovery News
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves The Medicine Maker
Background: Endometriosis is traditionally conceptualized as a localized gynecological disorder characterized by the presence of ectopic endometrial tissue. However, high recurrence rates following apparently complete surgical excision challenge this lesion-based …
This case-control study investigated whether ovarian endometriosis is associated with altered estrogen metabolism and gut or urogenital microbiota by analyzing enzyme activity, bacterial composition, and variations of estrogen metabolites in …
Endometriosis (EMS) is a chronic inflammatory disorder affecting ~10% of reproductive-age women, with increasing evidence implicating the microbiome in its pathogenesis through immunomodulation and estrogen metabolism. This study investigated microbiome …
Sex hormone related disorders, characterized by complex etiology and long-term health risks, pose a significant challenge to global health. Hormone-based therapies are often accompanied by adverse effects and fail to …
Endometriosis has been associated with alterations in the reproductive tract microbiota, yet studies focusing on the endometrial microbiome remain inconsistent, partly due to the low-biomass nature of this niche and …
How can the potential mechanisms and targets of endometriosis be explored through multi-omics and multi-location approaches?
Endometriosis and polycystic ovary syndrome (PCOS) are common, multifactorial gynecological disorders shaped by endocrine imbalance, immune dysfunction, metabolic disruption, genetic susceptibility, and environmental exposures. Despite their major contribution to infertility …